It’s very unusual to see significant cost savings in the first year of a program; that was true of all the pioneer ACO programs, said Jeff Patton, MD, CEO of Tennessee Oncology.
It’s very unusual to see significant cost savings in the first year of a program; that was true of all the pioneer ACO programs, said Jeff Patton, MD, CEO of Tennessee Oncology.
Transcript (slightly modified)
We have what we call the 4 pillars. We do pathways with the oncology pathways; we’ve built a triage platform on the sales force platform for nurse triage; we’ve partnered with Aspire, which is a palliative care company; and then we’ve hired care coordinators, and that’s probably the least defined of the 4 pillars because I’m not sure we know what the perfect way is. We know it’s important, but I’m not sure we’ve figured out how to make it work.
What steps have you taken to prepare your practice for OCM?
What’s the capital investment for implementing OCM, and how much time do you think it will take for a practice to see improved patient outcomes and cost savings?
It’s very unusual to see significant cost savings in the first year of a program; that was true of all the pioneer ACO programs. So, whether we’ll see more than 7% in the first year, we don’t know. That’s our math because the first 4% goes back to CMS, but then you have to pay back your MEOS payments, and that’s about 3% by our calculation. So, whether we’ll realize those type of savings, we don’t know. We do have feedback for the last 3 quarters; our ER visits have gone down and our hospitalizations have gone down, so we know we’re saving some money. But, we may be more than making up for those savings by adopting novel therapies. So that’s on the savings side.
On the investment side, I don’t have an exact number for you, but I’ve heard published data that it probably cost between, if you do everything right, $225-$250 per member per month, and we’re getting paid $160, so it’s a big investment. We’ve invested in the pathways, we’ve invested in the triage system, and then we’ve hired quite a few people, quite a few billers, abstracters, care coordinators. We’ve increased our number of medical assistants because they’re the ones entering most of the data. It’s a significant capital investment.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More